Spago Nanomedical AB (publ) (SPAGO.ST) Research

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.

Market snapshot

Symbol
SPAGO.ST
Price
$0.12
Day change
+4.91%
Market cap
$39.6M
P/E ratio
-2.10x
52-week range
0.0842-0.46
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AcouSort AB (publ) (ACOU.ST)
  • Active Biotech AB (publ) (ACTI.ST)
  • Alligator Bioscience AB (publ) (ATORX.ST)
  • Scandinavian Real Heart AB (Publ) (HEART.ST)
  • Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
  • OncoZenge AB (publ) (ONCOZ.ST)
  • Pila Pharma AB (publ) (PILA.ST)
  • Simris Alg AB (publ) (SIMRIS-B.ST)

Open Spago Nanomedical AB (publ) (SPAGO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.